Shattuck Labs Announces Participation in Upcoming January Investor Conferences
Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology firm, announced its participation in two virtual investor conferences this January 2022. CEO Taylor Schreiber will present at the H.C. Wainwright BioConnect 2022 Conference on January 10 at 7:00 a.m. EST and the 40th Annual J.P. Morgan Healthcare Conference on January 13 at 11:15 a.m. EST. The company is advancing bi-functional fusion proteins targeting cancer and autoimmune diseases, with three ongoing Phase 1 clinical trials. Webcasts will be available live and archived for 90 days on their website.
- Participation in two notable investor conferences can enhance market visibility and investor interest.
- Ongoing Phase 1 trials for multiple candidate products indicate active development in innovative cancer therapies.
- None.
AUSTIN, TX and DURHAM, NC, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease with three ongoing Phase 1 clinical trials, today announced that company management will participate in two virtual investor conferences in January 2022.
Presentation Details
Conference: H.C. Wainwright BioConnect 2022 Conference
Format: Corporate Presentation
Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer
Date: January 10, 2022
Time: 7:00 a.m. EST
Conference: 40th Annual J.P. Morgan Healthcare Conference
Format: Corporate Presentation
Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer
Date: January 13, 2022
Time: 11:15 a.m. EST
A live webcast of both presentations will be available on the Events & Presentations section of the Company’s website. A replay of the webcasts will be archived for up to 90 days following the presentation date.
About Shattuck Labs, Inc.
Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s SL-172154 (SIRPα-Fc-CD40L) program, which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in two Phase 1 trials. A second product candidate, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in solid tumors or lymphomas. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.
Investor Contact:
Conor Richardson
Senior Director, Finance & Investor Relations
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com
Media Contact:
Stephanie Ascher
Managing Director
Stern Investor Relations, Inc.
Stephanie.ascher@sternir.com
FAQ
What are the investor conferences Shattuck Labs is participating in January 2022?
Who will present at the Shattuck Labs investor conferences?
What is Shattuck Labs focused on in its clinical trials?
When can I watch the presentations from Shattuck Labs?
What candidates are involved in Shattuck Labs' clinical trials?
